



Interfering with *CALCRL* expression inhibits glioma proliferation, promotes apoptosis, and predicts prognosis in low-grade gliomas

Shengcai Gu^{1#}, Lei Shu^{2#}, Lv Zhou¹, Yuxin Wang², Hanying Xue², Lan Jin², Zhiyu Xia², Xingliang Dai^{1^}, Peng Gao³, Hongwei Cheng¹

¹Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Hefei, China; ²Department of Clinical Medicine, the First Clinical College of Anhui Medical University, Hefei, China; ³Department of Neurosurgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China

Contributions: (I) Conception and design: H Cheng, P Gao, X Dai; (II) Administrative support: H Cheng; (III) Provision of study materials or patients: S Gu, L Shu, L Zhou, Y Wang; (IV) Collection and assembly of data: H Xue, L Jin, Z Xia; (V) Data analysis and interpretation: L Shu, X Dai; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Hongwei Cheng. Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei 230022, China. Email: hongwei.cheng@ahmu.edu.cn; Peng Gao. Department of Neurosurgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China. Email: gaopeng@ahmu.edu.cn; Xingliang Dai. Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei 230022, China. Email: daixingliang@ahmu.edu.cn.

Background: *CALCRL* is involved in a variety of key biological processes, including cell proliferation, apoptosis, angiogenesis, and inflammation. However, the role of *CALCRL* in glioma remains unknown. The purpose of this study was to investigate the effect of differential *CALCRL* expression on the malignant progression of glioma and its value in glioma prognosis.

Methods: Sequencing data from glioma and normal tissues were downloaded from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases, and the downloaded data were statistically analyzed using bioinformatics tools and the corresponding R package. The expression of *CALCRL* in normal brain tissue and different grades of glioma tissue was detected by pathological and immunohistochemical staining of clinical glioma specimens. The expression of *CALCRL* in different glioma cell lines was detected by quantitative real-time polymerase chain reaction (qRT-PCR), and the U87 cell line with high expression was selected to construct the *CALCRL* knockdown model by transfection with short hairpin (shRNA). The cell proliferation ability was detected by Celigo assay and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, the ability of cell clone formation was detected by clone formation assay, and the level of apoptosis was detected by flow cytometry.

Results: The expression of *CALCRL* in glioma was significantly upregulated compared with that of normal tissue, especially in low-grade glioma (LGG) compared to glioblastoma, and the differential expression of *CALCRL* correlated significantly with the prognosis of LGG. Clinical pathology and immunohistochemistry showed that the expression of *CALCRL* was related to the pathological grade of glioma, and the highest expression was found in World Health Organization (WHO) grade III glioma. The results of qRT-PCR showed that *CALCRL* expression was highest in the U87 cell line. After knockdown of *CALCRL* expression, the proliferation and clonogenic ability of U87 cells were significantly decreased, and the apoptosis rate was significantly increased.

Conclusions: *CALCRL* is highly expressed in LGG. Interfering with *CALCRL* expression inhibits glioma cell proliferation and promotes apoptosis, and thus has potential as a biomarker and therapeutic target for the prognosis of those with LGGs.

Keywords: Glioma; *CALCRL*; bioinformatics; proliferation; apoptosis

[^] ORCID: 0000-0002-0685-4766.

Submitted Sep 29, 2022. Accepted for publication Nov 29, 2022.

doi: 10.21037/atm-22-5154

View this article at: <https://dx.doi.org/10.21037/atm-22-5154>

Introduction

Glioma is the most common and aggressive primary malignant tumor of the central nervous system in adults, accounting for nearly 30% of primary brain tumors and 80% of all malignant brain tumors (1,2). According to the World Health Organization (WHO) grading system, grades II and III are classified as low-grade gliomas (LGGs), with grade IV gliomas being considered glioblastomas (GBMs) (3-5). The 5-year survival rate for patients with LGGs ranges from 49% to 93% (6), and the median overall survival (OS) for patients with grade II and III gliomas is 78.1 and 37.6 months, respectively (7). Although LGGs are inert precursors of GBMs and less aggressive, due to the heterogeneity of clinical manifestations, they still lead to a high incidence rate and poor prognosis, posing challenges to treatment (8,9). The tumor boundary of LGG surgery is difficult to define, complete surgical resection is considered impossible, and local recurrence and malignant progression are inevitable despite a combination of adjuvant radiotherapy and chemotherapy treatments (10-12). Therefore, it is necessary to further explore the exact pathogenesis of LGGs and the molecular mechanisms that affect the malignant biological behavior in order to develop new treatments.

The *CALCRL* gene, located on chromosome 2q32.1,

encodes for a 7-transmembrane G protein-coupled receptor that mediates the pleiotropic effects of calcitonin gene-related peptide (CGRP) and adrenomedullin (ADM), 2 structurally related neuropeptides originally described as potent vasodilators (13). *CALCRL* is involved in a variety of key biological processes, including cell proliferation, apoptosis, angiogenesis, and inflammation (14-16). Antibody-mediated inhibitors of the *CALCRL* signaling pathway have shown therapeutic activity in malignant solid tumors, including GBM, melanoma, and prostate tumors (17), and it has also emerged as a novel target for the treatment of migraine (18). Low *CALCRL* expression has been found in lung adenocarcinoma and to act as a prognostic marker and potential tumor suppressor (19), while high *CALCRL* expression has been associated with glioma (20). However, thus far, no report exists concerning the expression of *CALCRL* in broad-spectrum tumors, particularly glioma, and its impact on patient survival. Therefore, the role of *CALCRL* in glioma needs to be further investigated and its prognostic value in LGGs clarified.

The aim of this study was thus to investigate the expression of *CALCRL* in glioma and its impact on the malignant behavior of glioma. We analyzed the expression of *CALCRL* in different tumors using The Cancer Genome Atlas (TCGA) database and the OncoPrint database, as well as the differential expression of *CALCRL* in LGGs and GBMs. The expression of *CALCRL* in glioma clinical specimens was then verified at the tissue level by immunohistochemical staining. Finally, a *CALCRL*-knockdown cell model was constructed via lentiviral transfection, and the effects of *CALCRL* on glioma cell proliferation and apoptosis were investigated. Our results provide preliminary insights into the regulation of *CALCRL* in glioma and provide a reference for the treatment of glioma. We present the following article in accordance with the MDAR reporting checklist (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-5154/rc>).

Methods

Data acquisition

With the widespread application of microarrays and high-

Highlight box

Key findings

- Compared with normal tissues, *CALCRL* is highly expressed in gliomas, and this is related to the prognosis of glioma. Interfering with the expression of *CALCRL* can inhibit the proliferation and promote apoptosis of glioma cells.

What is known and what is new?

- Glioma is the most common and aggressive malignant tumor in the central nervous system with poor prognosis. *CALCRL* is involved in a variety of key biological processes and is related to the malignant progression of many tumors, as well as glioma.
- The effect of *CALCRL* expression on malignant progression of glioma and its prognostic value in glioma is new sight.

What is the implication, and what should change now?

- It provides a new biomarker and potential therapeutic target for the prognosis and treatment of glioma.

throughput sequencing, a large amount of genomics data has accumulated in the field of cancer research, in databases like TCGA (<https://portal.gdc.cancer.gov/>) (21). RNA sequencing (RNA-seq) data of glioma were obtained from TCGA database, while RNA-seq data of normal samples were obtained from the Genotype-Tissue Expression (GTEx) database. Patient data with significantly missing information were excluded. This study complies with the publication guidelines developed by TCGA.

Oncomine database analysis

Oncomine (<https://www.oncomine.org/resource/login.html>) is currently the world's largest cancer-related gene microarray database and integrated data-mining platform, collecting the most complete spectrum of cancer mutations, associated gene expression profiles, and relevant clinical information (22). In this study, we selected the *CALCRL* gene as the subject and compared its expression levels in tumor tissues and normal tissues. We set the threshold for gene ranking to “top 10%” and the data type to “all”.

Analysis of the Gene Expression Profiling Interactive Analysis 2 (GEPIA2) database

GEPIA2 (<http://gepia.cancer-pku.cn/>) is a website for online analysis of cancer expression profiles. The database contains 9,736 tumor samples and 8,587 normal samples from TCGA and GTEx (23). It can provide online analyses of TCGA database. GEPIA2 was used to verify the differential expression of *CALCRL* in glioma tissue and normal tissue.

Data analysis

Statistical analysis and visualization were performed using the corresponding R package (version 4.0.3). *CALCRL* in glioma and GTEx did not conform to normal distribution, so the Mann-Whitney test (Wilcoxon rank sum test) was used to compare the expression differences between the tumor group and normal group. The Kruskal-Wallis test is an extension of the Mann-Whitney test and is a type of nonparametric test used for multiple independent samples. The Kruskal-Wallis test was used to compare the differential expression between LGGs, high-grade gliomas, and normal tissue. The diagnostic value of *CALCRL* for glioma was determined by receiver operating characteristic (ROC) curve. Univariate cox regression analysis was

applied, and a forest plot was drawn using the “forestplot” R package to calculate the P value, hazard ratio, and 95% confidence interval (CI). A P value <0.05 was considered statistically significant. The significance levels were as follows: *P<0.05, **P<0.01, and ***P<0.001.

Clinical specimen collection

The human brain tissue specimens used in this experiment were collected from the Neurosurgery Department of the First Affiliated Hospital of Anhui Medical University and included 62 glioma specimens and 10 normal brain tissue specimens. All glioma specimens were primary and were not subject to radiotherapy or chemotherapy before operation. All glioma specimens were resected for the first time, and the diagnosis was confirmed by postoperative pathological testing. Grading the 62 glioma specimens using the WHO's neuroepithelial tumor criteria (2016 version) yielded the following results: 6 grade I gliomas, 22 grade II, 16 grade III, and 18 grade IV. Furthermore, 10 samples of normal brain tissue were obtained from the brain tissue removed during internal decompression surgery in patients with traumatic brain injury. All specimens were immediately frozen in liquid nitrogen after surgical removal and preserved for use. Informed consent was obtained from the patients for the acquisition and use of all specimens, and the study was approved by the Ethics Committee of the First Affiliated Hospital of Anhui Medical University (No. P2020-12-07). The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Hematoxylin and eosin (HE) staining

Glioma and normal tissues were fixed in 4% paraformaldehyde, dehydrated with alcohol, and embedded in paraffin to prepare tissue wax. The wax blocks were continuously sliced into 5 µm-thick sections, which were then dewaxed in xylene. After being dewaxed, the tissue sections were stained with hematoxylin staining solution, differentiated with 1% hydrochloric acid alcohol for 3 seconds, stained with 1% eosin staining solution for 1 minute, dehydrated, made transparent, sealed, and observed under an optical microscope.

Immunohistochemical staining

After being dewaxed, tissue sections were incubated in

3% hydrogen peroxide solution for 15 minutes to block endogenous peroxidase activity. Sections were fully immersed in antigen repair solution and subjected to heat-mediated antigen repair using an autoclave heated to maximum pressure for 3 minutes, cooled, and rinsed 3 times with phosphate-buffered saline (PBS). Closure solution was added in dropwise fashion. Subsequently, appropriate dilutions of *CALCRL* (Bioss, Beijing, China) primary antibody were added dropwise to the tissue sections and incubated overnight at 4 °C. After washing, an appropriate amount of goat anti-rabbit immunoglobulin G (IgG) working solution (Bioss) was added dropwise to the sections, DAB (3,3-diaminobenzidine) was developed, and hematoxylin staining was reapplied. The sections were then dehydrated, made transparent, sealed, observed, analyzed, and photographed under a microscope. The staining results were scored simultaneously by 2 experienced pathologists. The staining result score was determined by a combination of staining intensity and percentage of positive cells and calculated according to the following formula: total staining score = intensity score × percentage score.

Cell culture

The human glioma cell lines (SHG44, SU3, SU2, U87, U251, U343, and A172) were obtained from the Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University. A complete medium was prepared by adding 10% fetal bovine serum, 1% penicillin, and 1% streptomycin in Dulbecco's Modified Eagle's medium (DMEM). The cells were cultured in complete medium in a constant temperature incubator at 37 °C with a 5% CO₂ atmosphere and saturated humidity. Cells were passaged when the cell fusion rate reached 80% and stably passaged to the third or fourth generation for subsequent cell experiments.

Lentiviral transfection

U87 cells were divided into 3 treatment groups: shCtrl (negative control), sh*CALCRL*#1 (knockdown group 1), and sh*CALCRL*#2 (knockdown group 2). The sh*CALCRL*#1 target sequence was CTTATCTCGCTTGGCATATTC, and the sh*CALCRL*#2 target sequence was TTACCTGATGGGCTGTAATTA. U87 cells were inoculated into 6-well plates, and transfection enhancement reagents and an appropriate amount of virus were added to the

6-well plates. After 16 h of transfection, the cells were changed and incubated for 72 h. The expression of the green fluorescent protein (GFP) was observed under a fluorescent microscope to initially test the transfection efficiency. After a 24-h culture, relevant experiments were carried out.

Quantitative real-time polymerase chain reaction (qRT-PCR)

The cells were lysed by TRIzol and total RNA was isolated. The absorbance value of the extracted RNA was measured by NanoDrop2000 (Thermo Fisher Scientific, Waltham, MA, USA). When 1.8 <OD₂₆₀/OD₂₈₀ <2.0, the extracted RNA was considered to be of good purity and could be used for subsequent experiments. Reverse transcription primers (2 µL) and total RNA were added to the p PCR tubes for the reaction to obtain complement DNA (cDNA) according to the kit instructions. The process of configuring the reverse transcription system was carried out on ice. Quantitative real-time PCR (qRT-PCR) was performed using the Ultra SYBR mixture, and the relative expression of genes was finally analyzed by the 2^{-ΔΔCt} method, with GAPDH as the internal reference. The primer sequences used during qRT-PCR were the following: *CALCRL* forward primer 5'-GCAGCAGCTACCTAGCTTGAA-3' and reverse primer 5'-TTCACGCCTTCTTCCGACTC-3', GAPDH-F: 5'GGCCTCCAAGGAGTAAGAAA, GAPDH-R: 5'GCCCCTCCTGTTATTATGG.

Celigo cell count assay

The cells were digested with trypsin at the logarithmic growth stage and prepared as a single cell suspension. The cell suspension was then homogeneously inoculated into 96-well plates containing 100 µL of complete medium at approximately 1.5×10³ cells per well, which was followed by incubation at 37 °C in a 5% CO₂ atmosphere. Cells were examined once daily for 5 days starting the day after plate laying using a Celigo full-field cell scanning analyzer (Nexcelom, Germany). The number of cells in each well was accurately recorded and photographed, and the proliferation curve was finally plotted.

MTT experiments

Single cell suspensions were prepared from cells in the

logarithmic growth phase and inoculated uniformly into 96-well plates. Each well contained 100 μ L of complete medium and approximately 2×10^3 cells. After 24 hours, 20 μ L of MTT solution at a concentration of 5 mg/mL was added to each well and incubated for 4 h. All liquid in the wells was then aspirated, and 100 μ L of methanogenic pellets dissolved in dimethyl sulfoxide (DMSO) was added to each well. The 96-well plate was placed on a shaker and shaken well for 2 to 5 min to completely dissolve the crystals. The 96-well plate was then placed in an enzyme marker, and the absorbance values were measured at optical density (OD) 490 nm. The subsequent data were exported and recorded in detail. The same method was used for 5 consecutive days, with the data being statistically analyzed at the end.

Plate clone formation experiments

Single cell suspensions were prepared from cells in the logarithmic growth phase, and 1,000 cells were counted and inoculated in 6-well plates and incubated for 10 min with slow shaking being used to evenly disperse the cells. The cells were incubated at 37 °C in a 5% CO₂ incubator for 12 days. The cell culture medium was carefully discarded, and the cell clones were fixed using methanol and then stained with crystal violet for 5 min. A cell count of >50 cells was set as 1 valid cell clone. The number of cell clones formed in each well was counted under a microscope, and the subsequent data were statistically analyzed.

Detection of apoptosis by flow cytometry

Single cell suspensions were prepared by taking 1×10^6 cells at the logarithmic growth stage. Cells were washed twice with PBS and $1 \times$ binding buffer. The cells were then resuspended with 500 μ L of $1 \times$ binding buffer and stained for 10 to 15 min at room temperature using the Annexin V staining kit (eBioscience, USA). After this, 5 μ L of propidium iodide (PI) was then added to stain the cells. The entire liquid containing the cells was transferred into a flow tube and tested on the flow cytometer (Millipore, France).

Statistical analysis

Data analyses were performed by GraphPad Prism version 8.0.2. All enumeration data were shown as mean \pm SD and were analyzed by Student's *t*-test. $P < 0.05$ was considered to

be statistically significant.

Results

CALCRL was highly expressed in glioma

In order to explore the role of *CALCRL* in tumor progression, we first analyzed the transcript levels of *CALCRL* in various tumor tissue types through the Oncomine database. The results showed that the *CALCRL* gene was generally highly expressed in all tumor types except kidney cancer, lung cancer, and sarcoma tissue (*Figure 1A*). RNA-seq data from all tumor samples in TCGA database and normal tissue samples in the GTEx database were analyzed, and the transcription levels of *CALCRL* in various tumors were compared. We found that *CALCRL* was significantly highly expressed in GBM and LGG (*Figure 1B*). The Wilcoxon rank sum test was used to calculate the differential expression between glioma and normal tissues. The results showed that there was a significant difference in the expression of *CALCRL* between glioma and normal tissues (*Figure 1C*). Analysis of the GEPIA2 database showed that *CALCRL* expression was significantly upregulated in LGG and GBM compared to normal tissue (*Figure 1D,1E*).

The relationship between CALCRL expression and clinical features of glioma and prediction of prognosis in LGG

We used the R package, “ggplot2”, to statistically analyze the data from TCGA and GTEx. A P value < 0.05 was considered statistically significant, and the results indicated that *CALCRL* expression was higher in LGG compared to GBM (*Figure 2A*). We determined whether there were significant differences in the expression of *CALCRL* in different clinical features between WHO grade II and III glioma. The results showed that *CALCRL* expression remained significantly different in LGG, with higher expression in WHO grade II gliomas compared to grade III gliomas, and decreased expression with increasing glioma grade (*Figure 2B*). The isocitrate dehydrogenase (IDH) in WHO grade II and III glioma was divided into a wild type (WT) and mutant type (MT). The difference in *CALCRL* expression between the 2 groups was statistically significant (*Figure 2C*). The time-dependent ROC curve showed that the area under the curve (AUC) of *CALCRL* for predicting survival outcome in patients with LGG was 0.979, indicating that *CALCRL* can be a good predictor of




Figure 1 *CALCRL* mRNA expression levels. (A) *CALCRL* expression levels in various normal or tumor tissues according to OncoPrint analysis. (B) *CALCRL* expression levels in different tumor types from TCGA database. (C) *CALCRL* expression levels in normal and glioma tissues. (D) The dot plot (the red dot represents tumor samples, and the green dot represents normal samples) and (E) box plot of *CALCRL* expression level in LGG, GBM and normal tissues according to GEPIA2 database analysis. *, $P < 0.05$; ***, $P < 0.001$. CNS, central nervous system; GBM, glioblastoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, low-grade glioma; LIHC, liver hepatocellular carcinoma; mRNA, messenger RNA; TCGA, The Cancer Genome Atlas; GTEx, Genotype-Tissue Expression.

patient survival (Figure 2D). To further explore whether *CALCRL* is an important prognostic factor for LGG, we performed univariate Cox regression analysis on RNA-seq data from TCGA, and the forest plot showed that *CALCRL* expression was significantly associated with the prognosis of LGG (Figure 2E).

CALCRL expression levels correlated with glioma pathological grade

To clarify the expression of *CALCRL* in clinical glioma surgical specimens and normal brain tissue, we performed HE staining and immunohistochemical staining on 62

glioma surgical specimens and 10 normal brain tissue specimens. We found that *CALCRL* expression was low in normal brain tissue; however, in glioma tissue, especially in WHO grade III glioma, *CALCRL* expression was significantly upregulated and higher compared to that in GBM (Figure 3).

CALCRL expression in glioma cell lines

To assess *CALCRL* expression in different glioma cell lines, we measured *CALCRL* messenger RNA (mRNA) levels in 7 glioma cell lines (SHG44, SU3, SU2, U87, U251, U343, and A172) and 2 normal astrocyte lines (HEB and HA1800)




Figure 2 (A) *CALCRL* expression in LGG, GBM, and normal tissues: G1 for LGG and G2 for GBM. (B) *CALCRL* expression in different WHO classifications: G2 for WHO grade II glioma and G3 for WHO grade III glioma. (C) *CALCRL* expression in different IDH mutant phenotypes. (D) Temporal ROC curves. (E) Forest plot. **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$. TPM, transcripts per million; WT, wild type; Mut, mutant type; TPR, true positive rate; FPR, false positive rate; GBM, glioblastoma; LGG, low-grade glioma; LIHC, liver hepatocellular carcinoma; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; IDH, isocitrate dehydrogenase; LAML, acute myeloid leukemia; ROC, receiver operating characteristic.

by qRT-PCR. The results showed a significantly different expression of *CALCRL* in the glioma cell lines compared to normal astrocytes (Figure 4A). U87, as the cell line with the highest *CALCRL* expression, was selected for subsequent *CALCRL* knockdown experiments. Short hairpin RNA (shRNA) was transfected in U87 cells to interfere with *CALCRL* expression, and stably transfected cell lines were constructed, with transfection efficiency being verified by qRT-PCR. The results showed that the expression level of *CALCRL* was reduced after transfection with shRNA, and the difference between the knockdown and control groups was statistically significant (Figure 4B). Specifically, the knockdown efficiency of sh*CALCRL*#1 group was greater than sh*CALCRL*#2, which was thus used in the follow-up experiment, and assign as sh*CALCRL*. The cell morphology and vector fluorescence expression before and after shRNA

transfection of U87 cells were observed under fluorescence microscope, and green fluorescence could be observed, indicating successful shRNA transfection (Figure 4C).

The effect of interference with CALCRL expression on the proliferation of glioma cells

The number of cells was dynamically detected by Celigo imaging for 5 consecutive days. We found that the number of U87 cells in the sh*CALCRL* group was significantly lower than that in the shCtrl group. Further calculation of the cell proliferation rate also revealed that the cell proliferation rate in the sh*CALCRL* group was significantly lower than that in the shCtrl group (Figure 5A,5B). Through cell viability analysis, we found that the number of viable U87 cells in the sh*CALCRL*




Figure 3 Pathology and immunohistochemistry of different grades of glioma specimens. (A) HE staining of different grades of glioma tissues. (B) *CALCRL* immunohistochemical staining of different grades of glioma tissues. The IHC staining results showed that there were few *CALCRL* staining-positive cells in the normal brain tissue, while a large number of *CALCRL* staining-positive cells were present in WHO grade II–IV glioma, especially WHO grade III glioma. Scale bar: left 400 μm , right 20 μm . HE, hematoxylin and eosin; IHC, immunohistochemical.

group was significantly lower than that in the shCtrl group, and further calculation of the cell proliferation rate showed that the cell proliferation rate in the sh*CALCRL* group was significantly lower than that in the shCtrl group (Figure 5C). This finding, in combination with the results of the Celigo assay and MTT assay, indicated that the knockdown of *CALCRL* gene could inhibit the proliferation of glioma cells.

Effect of interference with CALCRL expression on clone formation in glioma cells

The results of the clone formation assay showed that after interference with *CALCRL* expression in U87 cells, the clone formation rate of cells in the sh*CALCRL* group was significantly decreased compared with that in the shCtrl group, and the difference was statistically significant (Figure 6A–6C). The results indicated that interfering with *CALCRL* expression could inhibit the clone formation of glioma cells.

Effect of interference with CALCRL expression on apoptosis in glioma cells

Apoptosis resistance is a major feature of tumor, and promoting apoptosis in tumor cells has become one of the important strategies for antitumor therapy. By using Annexin V staining to assess the relationship between *CALCRL* gene downregulation and apoptosis in U87 cells.

The results showed that *CALCRL* knockdown significantly promoted apoptosis in U87 cells (Figure 7A–7C). Thus, this result suggests that interference with *CALCRL* expression induces apoptosis in glioma cells.

Discussion

Glioma is a highly aggressive malignant brain tumor with the ability to proliferate rapidly, but treating this disease is challenging due to the inability to form accurate prognoses and the limited treatment options (24,25). The pathogenesis of glioma is complex due to the expression of aberrant genes




Figure 4 Transfection of shRNA in U87 cells. (A) Expression of *CALCRL* in glioma cell lines and normal astrocytes. (B) qRT-PCR validation of *CALCRL* expression in U87 cells after shRNA interference (shCALCRL1 and shCALCRL2), with a knockdown efficiency of 64.22% and 59.72%, respectively. (C) Cell morphology and vector fluorescence expression before and after shRNA transfection. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$. Scar bar: 50 μm . qRT-PCR, quantitative real-time polymerase chain reaction.

that affect cell growth, aggressiveness, and angiogenesis (26). In general, lower-grade tumors grow more slowly and have a more favorable prognosis than do higher-grade tumors. However, pathological grading is not sufficient to predict the prognosis of patients with glioma (27). Therefore, there is a need to find more promising prognostic biomarkers and new therapeutic targets.

CALRL is a G protein-coupled neuropeptide receptor involved in the regulation of calcium ion concentration in cells. *CALCRL* is upregulated in certain tumor types such as acute myeloid leukemia (AML), Kaposi sarcoma, and Ewing sarcoma (28). High expression of *CALCRL* has been shown to be associated with poor prognosis in AML. Angenendt *et al.* found that knockdown of *CALCRL* significantly inhibited colony formation in human myeloid leukemia cell lines, suggesting that *CALCRL* may be a

potential therapeutic target in AML (13). In addition, Larrue *et al.* found that *CALCRL* depletion reduced the frequency of leukemic stem cells in relapse-initiating cells after *in vivo* chemotherapy (29). *CALCRL* plays a role in tumor progression by mediating CGRP and ADM. It has been demonstrated that CGRP and ADM exert a crucial action in enhancement of angiogenesis and promotion of tumor cell growth. Among them, autocrine or paracrine *CALCRL* signaling loops exert this effect (30,31). These results all suggest that *CALCRL* is closely associated with cancer. However, the exact role of *CALCRL* in glioma, and more generally in other cancers, remains to be determined.

In the present study, we evaluated the role of the rarely reported on *CALCRL* gene in glioma. Using TCGA and GTEx databases, we found that *CALCRL* is overexpressed in glioma, especially in LGG, plays a role in its diagnosis, and




Figure 5 Cell proliferation and viability analysis. (A) Celigo observations on the proliferation multiple of U87 cells over 5 days. Green fluorescent protein was observed under a fluorescent microscope (scale bar: 50 μ m). (B) Celigo experiment U87 cell proliferation curve: the cell proliferation cell multiple of the control group was significantly higher than that of the experimental group. (C) MTT assay showed that the proliferation curve of U87 cells in the control group was significantly higher than that in the experimental group. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.

is significantly associated with LGG prognosis. Pathological immunohistochemical staining of clinical glioma specimens indicated that *CALCRL* was overexpressed in LGG compared with GBM. Next, we explored the relationship between *CALCRL* expression levels and glioma biological properties using the U87 cell line. We knocked down the expression level of *CALCRL* in the U87 cell line using shRNA transfection and verified the transfection efficiency using qRT-PCR. The results of *in vitro* experiments showed that knockdown of *CALCRL* significantly inhibited the proliferation and clone formation of glioma cells while promoting the occurrence of apoptosis. In conclusion, *CALCRL* expression is associated with malignant biological processes and can be used as a

biomarker for glioma. The expression of *CALCRL* in glioma may be the key to the diagnosis and treatment of glioma.

Conclusions

CALCRL was significantly more highly expressed in LGG compared to normal tissue, and differential expression correlated significantly with LGG prognosis. Glioma cell proliferation was significantly slowed, cloning was reduced, and apoptosis was increased after interference with *CALCRL* expression. Thus, interference with *CALCRL* expression significantly inhibited glioma proliferation, promoted apoptosis, and predicted the prognosis of LGG and thus




Figure 6 The number of cell clones was significantly reduced after U87 cells were transfected with shCALCRL to interfere with expression: Visual observation of (A) experimental group and (B) control group after crystal violet staining. (C) Histogram of the number of cell clones in the experimental and control groups. ***, $P < 0.001$.




Figure 7 Apoptosis was significantly increased after U87 cells were transfected with shCALCRL to interfere with expression. (A) Experimental group and (B) control group. (C) Histogram of the apoptosis ratio between the experimental and control groups. ***, $P < 0.001$. APC, allophycocyanin.

may serve as a potential therapeutic target for glioma.

Acknowledgments

Funding: This study was supported by the Anhui Provincial

Natural Science Foundation (No. 2208085MH251), the Anhui Medical University Scientific Research Fund (No. 2021xkj131), and the Basic and Clinical Cooperative Research and Promotion Program of Anhui Medical University (No. 2022xkjT024).

Footnote

Reporting Checklist: The authors have completed the MDAR reporting checklist. Available at <https://atm.amegroups.com/article/view/10.21037/atm-22-5154/rc>

Data Sharing Statement: Available at <https://atm.amegroups.com/article/view/10.21037/atm-22-5154/dss>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-5154/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Informed consent was obtained from the patients for the acquisition and use of all specimens, and the study was approved by the Ethics Committee of the First Affiliated Hospital of Anhui Medical University (No. P2020-12-07).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

- Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions. *J Exp Clin Cancer Res* 2022;41:142.
- Chen Z, Ye N, Teng C, et al. Alternations and Applications of the Structural and Functional Connectome in Gliomas: A Mini-Review. *Front Neurosci* 2022;16:856808.
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol* 2021;23:1231-51.
- Ostrom QT, Cioffi G, Waite K, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. *Neuro Oncol* 2021;23:iii1-iii105.
- Suzuki H, Aoki K, Chiba K, et al. Mutational landscape and clonal architecture in grade II and III gliomas. *Nat Genet* 2015;47:458-68.
- Liu Y, Liu S, Li G, et al. Association of high-dose radiotherapy with improved survival in patients with newly diagnosed low-grade gliomas. *Cancer* 2022;128:1085-92.
- Li J, Wang J, Ding Y, et al. Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas. *BMC Cancer* 2022;22:466.
- Chen J, Wang Z, Wang W, et al. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data. *Int Immunopharmacol* 2020;84:106490.
- Guo Y, Li Y, Li J, et al. DNA Methylation-Driven Genes for Developing Survival Nomogram for Low-Grade Glioma. *Front Oncol* 2021;11:629521.
- Chen J, Shen S, Li Y, et al. APOLLO: An accurate and independently validated prediction model of lower-grade gliomas overall survival and a comparative study of model performance. *EBioMedicine* 2022;79:104007.
- Shankar GM, Kirtane AR, Miller JJ, et al. Genotype-targeted local therapy of glioma. *Proc Natl Acad Sci U S A* 2018;115:E8388-94.
- Wang Z, Cheng W, Zhao Z, et al. Comparative profiling of immune genes improves the prognoses of lower grade gliomas. *Cancer Biol Med* 2021;19:533-50.
- Angenendt L, Bormann E, Pabst C, et al. The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. *Leukemia* 2019;33:2830-41.
- Larráyoz IM, Martínez-Herrero S, García-Sanmartín J, et al. Adrenomedullin and tumour microenvironment. *J Transl Med* 2014;12:339.
- Russell FA, King R, Smillie SJ, et al. Calcitonin gene-related peptide: physiology and pathophysiology. *Physiol Rev* 2014;94:1099-142.
- Davis RB, Kechele DO, Blakeney ES, et al. Lymphatic deletion of calcitonin receptor-like receptor exacerbates intestinal inflammation. *JCI Insight* 2017;2:e92465.
- Angenendt L, Wöste M, Mikesch JH, et al. Calcitonin receptor-like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML. *Blood Adv* 2021;5:4413-21.
- Dodick DW. Migraine. *Lancet* 2018;391:1315-30.
- Lu M, Fan X, Liao W, et al. Identification of significant genes as prognostic markers and potential tumor

- suppressors in lung adenocarcinoma via bioinformatical analysis. *BMC Cancer* 2021;21:616.
20. Han T, Zuo Z, Qu M, et al. Comprehensive Analysis of Inflammatory Response-Related Genes, and Prognosis and Immune Infiltration in Patients With Low-Grade Glioma. *Front Pharmacol* 2021;12:748993.
 21. Zhang L, Peng R, Sun Y, et al. Identification of key genes in non-small cell lung cancer by bioinformatics analysis. *PeerJ* 2019;7:e8215.
 22. Xie XW, Jiang SS, Li X. CLEC3B as a Potential Prognostic Biomarker in Hepatocellular Carcinoma. *Front Mol Biosci* 2020;7:614034.
 23. Tang Z, Kang B, Li C, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. *Nucleic Acids Res* 2019;47:W556-60.
 24. Wu J, Tang X, Yu X, et al. TMEM60 Promotes the Proliferation and Migration and Inhibits the Apoptosis of Glioma through Modulating AKT Signaling. *J Oncol* 2022;2022:9913700.
 25. Zheng X, Wang Y, Wang D, et al. PSMC2 is overexpressed in glioma and promotes proliferation and anti-apoptosis of glioma cells. *World J Surg Oncol* 2022;20:84.
 26. Zhang F, Cai HB, Liu HZ, et al. High Expression of CISD2 in Relation to Adverse Outcome and Abnormal Immune Cell Infiltration in Glioma. *Dis Markers* 2022;2022:8133505.
 27. Li F, Zhang Y, Wang N, et al. Evaluation of the Prognosis of Neuroglioma Based on Dynamic Magnetic Resonance Enhancement. *World Neurosurg* 2020;138:663-71.
 28. Xing C, Yin H, Yao ZY, et al. Prognostic Signatures Based on Ferroptosis- and Immune-Related Genes for Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma. *Front Oncol* 2021;11:774558.
 29. Larrue C, Guiraud N, Mouchel PL, et al. Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells. *Nat Commun* 2021;12:422.
 30. Toda M, Suzuki T, Hosono K, et al. Neuronal system-dependent facilitation of tumor angiogenesis and tumor growth by calcitonin gene-related peptide. *Proc Natl Acad Sci U S A* 2008;105:13550-5.
 31. Chen P, Huang Y, Bong R, et al. Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. *Clin Cancer Res* 2011;17:7230-9.

(English Language Editor: J. Gray)

Cite this article as: Gu S, Shu L, Zhou L, Wang Y, Xue H, Jin L, Xia Z, Dai X, Gao P, Cheng H. Interfering with CALCRL expression inhibits glioma proliferation, promotes apoptosis, and predicts prognosis in low-grade gliomas. *Ann Transl Med* 2022;10(23):1277. doi: 10.21037/atm-22-5154